“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we’re in a unique position where we can stay really hyper-focused on what we’re doing. I’m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they’re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva’s doing right.” In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.

See omnystudio.com/listener for privacy information.